In this Section |
![]() 257125 Rate and predictors of persistent Major Depressive Disorder in a nationally representative sampleMonday, October 29, 2012
Objective: This study examined predictors of persistent major depressive disorder (MDD) over 10 years, focusing on the effects of clinical variables, physical health, and social support. Method: The National Survey of Midlife Development in the United States (MIDUS) in 1995-1996 and the follow-up in 2004-2006 were analyzed. Respondents were non-institutionalized English-speaking adults. Individuals who met clinical-based criteria for Major Depressive Disorder (MDD) at Time 1 were included in the analysis. Logistic regression was used with the baseline variables to predict non-recovery from MDD at follow-up. Results: Fifteen percent of the total sample was classified as having MDD in 1995-1996. Of those with MDD at baseline, 37% were also classified as having MDD in 2004-2006. Baseline variables that were associated with persistent MDD at follow-up were being female (OR=2.51; 95% CI: 1.28-4.92), having a comorbid anxiety disorder (OR=5.79; CI:2.29-14.62), having two or more chronic medical conditions (OR=2.61; 95% CI: 1.16-5.89), experiencing activity limitation (OR=2.45; CI: 1.96-4.41), and less contact with family (OR=2.41; CI: 1.40-4.27). Conclusion: A significant proportion of individuals experience persistent MDD after 10 years. Treatment strategies focused on physical health, social, and mental health needs are necessary to comprehensively address the factors that contribute to persistent MDD.
Learning Areas:
Public health or related researchLearning Objectives: Keywords: Depression, Chronic Diseases
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am a doctoral candidate focusing on mental health and chronic disease. I designed and conducted the analysis for this study. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 3291.0: Psychiatric epidemiology
|